JP6866535B2 - アミノ酸化合物および使用方法 - Google Patents

アミノ酸化合物および使用方法 Download PDF

Info

Publication number
JP6866535B2
JP6866535B2 JP2020521559A JP2020521559A JP6866535B2 JP 6866535 B2 JP6866535 B2 JP 6866535B2 JP 2020521559 A JP2020521559 A JP 2020521559A JP 2020521559 A JP2020521559 A JP 2020521559A JP 6866535 B2 JP6866535 B2 JP 6866535B2
Authority
JP
Japan
Prior art keywords
amino
butyl
tetrahydro
naphthylidine
butanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509890A (ja
Inventor
ジェイコブ・チャ
チェングオ・ドン
ティモシー・ホム
ラン・ジアン
カテリーナ・レフテリス
ホイ・リィ
デイビッド・ジェイ・モーガンズ・ジュニア
マヌエル・ムニョス
モーリーン・ライリー
ヤジュン・ジェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Priority to JP2021065309A priority Critical patent/JP7273882B2/ja
Publication of JP2021509890A publication Critical patent/JP2021509890A/ja
Application granted granted Critical
Publication of JP6866535B2 publication Critical patent/JP6866535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020521559A 2018-03-07 2019-03-07 アミノ酸化合物および使用方法 Active JP6866535B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021065309A JP7273882B2 (ja) 2018-03-07 2021-04-07 アミノ酸化合物および使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862639988P 2018-03-07 2018-03-07
US62/639,988 2018-03-07
US201862690933P 2018-06-27 2018-06-27
US62/690,933 2018-06-27
PCT/US2019/021243 WO2019173653A1 (en) 2018-03-07 2019-03-07 Amino acid compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021065309A Division JP7273882B2 (ja) 2018-03-07 2021-04-07 アミノ酸化合物および使用方法

Publications (2)

Publication Number Publication Date
JP2021509890A JP2021509890A (ja) 2021-04-08
JP6866535B2 true JP6866535B2 (ja) 2021-04-28

Family

ID=67844341

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020521559A Active JP6866535B2 (ja) 2018-03-07 2019-03-07 アミノ酸化合物および使用方法
JP2021065309A Active JP7273882B2 (ja) 2018-03-07 2021-04-07 アミノ酸化合物および使用方法
JP2023074346A Active JP7624025B2 (ja) 2018-03-07 2023-04-28 アミノ酸化合物および使用方法
JP2025006716A Pending JP2025081308A (ja) 2018-03-07 2025-01-17 アミノ酸化合物および使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021065309A Active JP7273882B2 (ja) 2018-03-07 2021-04-07 アミノ酸化合物および使用方法
JP2023074346A Active JP7624025B2 (ja) 2018-03-07 2023-04-28 アミノ酸化合物および使用方法
JP2025006716A Pending JP2025081308A (ja) 2018-03-07 2025-01-17 アミノ酸化合物および使用方法

Country Status (35)

Country Link
US (4) US10793564B2 (enExample)
EP (3) EP4328230A3 (enExample)
JP (4) JP6866535B2 (enExample)
KR (2) KR20250048478A (enExample)
CN (1) CN112135612B (enExample)
AU (1) AU2019230209B2 (enExample)
BR (1) BR112020018064A2 (enExample)
CA (1) CA3093225A1 (enExample)
CL (1) CL2020002290A1 (enExample)
CO (1) CO2020011085A2 (enExample)
CR (1) CR20200452A (enExample)
CU (1) CU24684B1 (enExample)
DK (1) DK3761980T3 (enExample)
EC (1) ECSP20063227A (enExample)
ES (1) ES2972512T3 (enExample)
FI (1) FI3761980T3 (enExample)
HR (1) HRP20240234T1 (enExample)
HU (1) HUE065887T2 (enExample)
IL (2) IL277146B2 (enExample)
JO (1) JOP20200212A1 (enExample)
LT (1) LT3761980T (enExample)
MD (1) MD3761980T2 (enExample)
MX (2) MX2020009253A (enExample)
PE (2) PE20201502A1 (enExample)
PH (1) PH12020551395A1 (enExample)
PL (1) PL3761980T3 (enExample)
PT (1) PT3761980T (enExample)
RS (1) RS65170B1 (enExample)
SA (1) SA520420102B1 (enExample)
SG (1) SG11202008609UA (enExample)
SI (1) SI3761980T1 (enExample)
SM (1) SMT202400155T1 (enExample)
TW (1) TWI892960B (enExample)
WO (1) WO2019173653A1 (enExample)
ZA (1) ZA202005437B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526818A (ja) * 2019-04-08 2022-05-26 プライアント・セラピューティクス・インコーポレイテッド アミノ酸化合物の剤形およびレジメン
JP2025081308A (ja) * 2018-03-07 2025-05-27 プライアント・セラピューティクス・インコーポレイテッド アミノ酸化合物および使用方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4076454A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
KR20230049584A (ko) * 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TW202235417A (zh) * 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) * 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
WO2023225119A1 (en) * 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2024235299A1 (zh) * 2023-05-17 2024-11-21 西藏海思科制药有限公司 一种羧基衍生物及其在医药上的应用
WO2025024590A1 (en) * 2023-07-24 2025-01-30 The Johns Hopkins University Compositions and methods to treat mucus-related diseases
WO2025067384A1 (zh) * 2023-09-28 2025-04-03 成都微芯药业有限公司 一类氨基酸整联蛋白抑制剂、其制备方法及其应用
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
TW202615060A (zh) * 2024-06-21 2026-04-16 美商艾拉倫製藥公司 用於肝外遞送之整合素配體

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361764B2 (en) 1996-12-13 2002-03-26 Societe L'oreal S.A. Insoluble s-triazine derivatives and their use as UV filters
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE396174T1 (de) 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
AU2003273310A1 (en) 2002-09-10 2004-04-30 Pharmacia And Upjohn Substituted aminoethers for the treatment of alzheimer's disease
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
PL2299987T3 (pl) 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
IN2015DN00099A (enExample) * 2012-07-18 2015-05-29 Univ Saint Louis
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
JP7170540B2 (ja) 2016-04-14 2022-11-14 マース インコーポレーテッド コク味を調節するためにカルシウム感知受容体活性を調節する化合物及びそれを含むペットフード製品
KR20190026001A (ko) * 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) * 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081308A (ja) * 2018-03-07 2025-05-27 プライアント・セラピューティクス・インコーポレイテッド アミノ酸化合物および使用方法
JP2022526818A (ja) * 2019-04-08 2022-05-26 プライアント・セラピューティクス・インコーポレイテッド アミノ酸化合物の剤形およびレジメン
JP7579805B2 (ja) 2019-04-08 2024-11-08 プライアント・セラピューティクス・インコーポレイテッド アミノ酸化合物の剤形およびレジメン

Also Published As

Publication number Publication date
DK3761980T3 (da) 2024-01-29
IL277146B2 (en) 2024-02-01
IL277146B1 (en) 2023-10-01
JP2023106425A (ja) 2023-08-01
TW201938158A (zh) 2019-10-01
NZ767658A (en) 2024-11-29
JP2025081308A (ja) 2025-05-27
CU20200066A7 (es) 2021-04-07
US20210017171A1 (en) 2021-01-21
CN112135612A (zh) 2020-12-25
EP4328230A3 (en) 2024-04-24
FI3761980T3 (fi) 2024-02-21
LT3761980T (lt) 2024-03-12
EP4509512A3 (en) 2025-04-09
PL3761980T3 (pl) 2024-06-10
RS65170B1 (sr) 2024-02-29
EP3761980B1 (en) 2023-11-29
CR20200452A (es) 2020-11-19
HRP20240234T1 (hr) 2024-04-26
ES2972512T3 (es) 2024-06-13
US20190276449A1 (en) 2019-09-12
JOP20200212A1 (ar) 2020-09-01
MX2020009253A (es) 2021-01-15
PH12020551395A1 (en) 2021-11-22
EP4509512A2 (en) 2025-02-19
IL305296A (en) 2023-10-01
BR112020018064A2 (pt) 2020-12-22
JP7624025B2 (ja) 2025-01-29
EP4328230A2 (en) 2024-02-28
WO2019173653A1 (en) 2019-09-12
CL2020002290A1 (es) 2021-01-15
IL277146A (en) 2020-10-29
MD3761980T2 (ro) 2024-09-30
PE20251320A1 (es) 2025-05-16
KR20200139676A (ko) 2020-12-14
US20230271960A1 (en) 2023-08-31
SG11202008609UA (en) 2020-10-29
US20250223288A1 (en) 2025-07-10
ZA202005437B (en) 2024-06-26
AU2019230209B2 (en) 2024-02-01
KR102787602B1 (ko) 2025-03-31
PT3761980T (pt) 2024-02-29
KR20250048478A (ko) 2025-04-08
MX2022014456A (es) 2022-12-08
HUE065887T2 (hu) 2024-06-28
JP7273882B2 (ja) 2023-05-15
JP2021119140A (ja) 2021-08-12
AU2019230209A1 (en) 2020-09-24
SA520420102B1 (ar) 2024-10-20
SMT202400155T1 (it) 2024-05-14
US10793564B2 (en) 2020-10-06
CN112135612B (zh) 2025-06-17
PE20201502A1 (es) 2020-12-29
CO2020011085A2 (es) 2020-12-10
CU24684B1 (es) 2023-10-06
SI3761980T1 (sl) 2024-06-28
ECSP20063227A (es) 2020-11-30
EP3761980A4 (en) 2021-10-27
US11560376B2 (en) 2023-01-24
TWI892960B (zh) 2025-08-11
JP2021509890A (ja) 2021-04-08
CA3093225A1 (en) 2019-09-12
EP3761980A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7624025B2 (ja) アミノ酸化合物および使用方法
US12390463B2 (en) Dosage forms and regimens for amino acid compounds
EP4520329A2 (en) Treatment of respiratory diseases with amino acid compounds
TW202308637A (zh) 整合素抑制劑之擴大劑量方案
HK40106342A (en) Amino acid compounds and methods of use
HK40037094B (en) Amino acid compounds and methods of use
HK40037094A (en) Amino acid compounds and methods of use
OA20261A (en) Amino acid compounds and methods of use.
BR122024019819A2 (pt) Compostos de aminoácidos, seus usos e composição farmacêutica dos mesmos
EA047334B1 (ru) Аминокислотные соединения и способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201013

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201013

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210407

R150 Certificate of patent or registration of utility model

Ref document number: 6866535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250